Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis
- 28 February 2007
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Clinical Rheumatology
- Vol. 26 (11), 1871-1875
- https://doi.org/10.1007/s10067-007-0596-z
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Clinical characteristics and outcomes of Takayasu's arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classificationScandinavian Journal of Rheumatology, 2005
- Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritisRheumatology, 2005
- Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent?Rheumatology, 2005
- Anti–tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritisArthritis & Rheumatism, 2004
- Takayasu arteritis: a reviewJournal of Clinical Pathology, 2002
- Surrogate markers of disease activity in patients with Takayasu arteritis: A preliminary report from The International Network for the Study of the Systemic Vasculitides (INSSYS)International Journal of Cardiology, 1998
- Takayasu arteritis: lessons from the American National Institutes of Health experienceInternational Journal of Cardiology, 1996
- MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL ALLOGRAFT RECIPIENTSTransplantation, 1995
- Medical treatment of Takayasu arteritisHeart and Vessels, 1992
- The American College of Rheumatology 1990 criteria for the classification of takayasu arteritisArthritis & Rheumatism, 1990